AgomAb Therapeutics (NASDAQ:AGMB) Stock: Insider David Epstein Acquires 14,980 Shares

AgomAb Therapeutics NV (NASDAQ:AGMB – Get Free Report) Director David Epstein acquired 14,980 shares of the company’s stock in a transaction that occurred on Friday, November 13th. The shares were acquired at an average price of $5.92 per share, with a total value of $88,681.60. Following the acquisition, the director owned 54,980 shares in the company, valued at $325,481.60. This trade represents a 37.45% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

AgomAb Therapeutics Stock Performance

AGMB stock opened at $6.36 on Monday. AgomAb Therapeutics NV has a twelve month low of $5.73 and a twelve month high of $17.82. The business’s fifty day simple moving average is $9.57 and its two-hundred day simple moving average is $11.73.

Analysts Set New Price Targets

Several equities research analysts have issued reports on AGMB shares. Piper Sandler started coverage on shares of AgomAb Therapeutics in a research report on Tuesday, August 25th. They issued an “overweight” rating and a $60.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating on shares of AgomAb Therapeutics in a research report on Wednesday, October 21st. Wall Street Zen cut AgomAb Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, September 27th. Cantor Fitzgerald began coverage on AgomAb Therapeutics in a report on Wednesday, August 19th. They set an “overweight” rating on the stock. Finally, Johnson Rice reaffirmed a “buy” rating on shares of AgomAb Therapeutics in a research report on Wednesday, October 21st. Eight analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, AgomAb Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $37.50.

View Our Latest Analysis on AGMB

AgomAb Therapeutics Company Profile

(Get Free Report)

Agomab Therapeutics is a clinical-stage biopharmaceutical company developing medicines for fibrotic and inflammatory diseases. Its research focuses on growth-factor pathways involved in tissue repair and fibrosis. The company’s pipeline includes AGMB-129, an oral, gut-restricted inhibitor of the TGF-β receptor ALK5 being developed for fibrostenotic Crohn’s disease, and AGMB-447, an inhaled therapy targeting integrins for fibrotic lung disease. Agomab is also developing antibody-based approaches to fibrosis.

Read More

Insider Buying and Selling by Quarter for AgomAb Therapeutics (NASDAQ:AGMB)

Receive News & Ratings for AgomAb Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AgomAb Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.